Description
The FY26 Reconstructive Transplant Research Program (RTRP) Investigator‑Initiated Research Award provides up to $1 M per award to support innovative basic, translational, or pre‑clinical research related to vascularized composite allotransplantation (VCA) and associated immunology, preservation, biomarkers, and outcome measurement. Eight awards are expected, each with a maximum three‑year performance period. Projects must demonstrate solid scientific rationale, include preliminary data, and have clear military relevance to service‑member or veteran health. Clinical trials are excluded; however, studies may use human anatomical specimens or involve human subjects under strict regulatory oversight. Applications require a pre‑application (Letter of Intent) due 21 Oct 2026 and a full application due 4 Nov 2026. Funding is administered by the Defense Health Agency’s CDMRP under a grant instrument.
• Funding ceiling: $1 M total cost per award (max 3 yr).
• Total FY26 funding: $8 M for ~8 awards.
• Eligible applicants: Any U.S. Department of Defense (DoD) organization (extramural or intramural), including for‑profit, non‑profit, domestic or foreign entities.
• Required deliverables: Annual technical progress reports, final report, and a transition plan.
• No cost‑sharing required; travel to one DoD‑sponsored meeting is allowable.
• Awards must be awarded by 30 Sep 2027 with performance start on the same date.